{"disease":{"id":"prevention-of-postmenopausal-osteoporosis","name":"Prevention of postmenopausal osteoporosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."},{"drug_id":"duavee","indication_name":"Prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"Bazedoxifene Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptors (ER) α and β","drug_class":"Estrogen agonist/antagonist combination","quality_score":65,"revenue":null,"mechanism":"Pairs conjugated estrogens with bazedoxifene to bind and activate estrogen receptors α and β with tissue-specific effects."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"prempro","guideline_body":"FDA label","recommendation":"PREMARIN is indicated for the prevention of postmenopausal osteoporosis. Therapy should only be considered for women at significant risk of osteoporosis, and non-estrogen medication should be carefully considered.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"premphase-14-14","guideline_body":"FDA label","recommendation":"PREMARIN is indicated for the prevention of postmenopausal osteoporosis. Therapy should only be considered for women at significant risk of osteoporosis, and non-estrogen medication should be carefully considered.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"duavee","guideline_body":"FDA label","recommendation":"DUAVEE is indicated for the prevention of postmenopausal osteoporosis in women with a uterus. Therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}